deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04037462

Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy

Sponsor: Barbara Ann Karmanos Cancer Institute

Conditions Immunotherapy Non-Small Cell Lung Cancer
Interventions Dexamthasone
Updated 18 times since 2019 Last updated: May 20, 2024 Started: Jul 7, 2021 Primary completion: Feb 23, 2022 Completion: Feb 23, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual

Other terminated trials from Barbara Ann Karmanos Cancer Institute

See all terminations from Barbara Ann Karmanos Cancer Institute

Listed as NCT04037462, this PHASE1/PHASE2 trial focuses on Immunotherapy and Non-Small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by Barbara Ann Karmanos Cancer Institute, it has been updated 18 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Feb 2022 · 11 months · monthly snapshot~Feb 2022 – ~Jan 2023 · 11 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Status: Completed → Terminated · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Terminated → Completed

  4. Feb 2023 — Apr 2023 [monthly]

    Terminated PHASE1_PHASE2

  5. Jan 2023 — Feb 2023 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

▶ Show 13 earlier versions

  1. Feb 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. Mar 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Feb 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    Status: Recruiting → Not Yet Recruiting

  4. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Jun 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  7. May 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  8. Apr 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  9. Feb 2020 — Apr 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  10. Jan 2020 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  11. Dec 2019 — Jan 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  12. Nov 2019 — Dec 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  13. Aug 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Barbara Ann Karmanos Cancer Institute
  • University of Michigan
  • VA Office of Research and Development
  • Wayne State University
Data source: VA Office of Research and Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations